1 Title page 2 3 SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten 4 weeks after the first reported case 5 6 Short title: SARS-CoV-2 seroprevalence in Sao Paulo 7 8 **Authors** 9 Beatriz H. Tess<sup>1</sup>, Celso F. H. Granato<sup>2,3</sup>, Maria Cecília Goi Porto Alves.<sup>4</sup>, Maria 10 Carolina Pintao<sup>2</sup>, Edgar Rizzatti<sup>2</sup>, Marcia C. Nunes<sup>5</sup>, Fernando C. Reinach<sup>6</sup> 11 12 13 14 **Affiliations** 15 16 <sup>1</sup>Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade 17 de São Paulo, São Paulo, Brasil 18 <sup>2</sup>Divisão de Pesquisa e Desenvolvimento, Grupo Fleury, São Paulo, Brasil 19 <sup>3</sup>Departamento de Medicina, Disciplina de Doenças Infecciosas, Escola 20 Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brasil 21 <sup>4</sup>Instituto de Saúde da Secretaria de Saúde do Estado de São Paulo, São 22 Paulo, Brasil 23 <sup>5</sup>Ibope Inteligência, São Paulo, Brasil 24 <sup>6</sup>Past affiliation: Departamento de Bioquímica, Instituto de Química, 25 Universidade de São Paulo; no current affiliation, São Paulo, Brasil NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Abstract (word count 100)

A population-based household survey was performed to estimate the prevalence of IgM and IgG to SARS-CoV-2 in residents of six districts in São Paulo City, Brazil. Serum samples collected from 299 randomly-selected adults and 218 cohabitants (N=517) were tested by chemiluminescence immunoassay ten weeks after the first reported case. Weighted overall seroprevalence was 4.7% (95% CI 3.0-6.6%). The low seroprevalence suggests that most of this population could still be infected. Serial serosurveys were initiated aiming to monitor the progress of the ongoing pandemic throughout the entire city. This may help inform public health authority decisions regarding prevention and control strategies.

- Keywords: COVID-19, SARS-CoV-2, epidemiological survey, adult, serological
- 42 test, Immunoglobulin M; Immunoglobulin G, Brazil

## Main text (word count 1705)

Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

The spread of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been continuing worldwide since December 2019. In Brazil, the first laboratory-confirmed case was reported on February 26, 2020. The patient was a 61-year-old male resident in São Paulo City, who had returned from a visit to Lombardy (Italy) a few days previously [1]. On March 13th, 2020, the Brazilian Ministry of Health declared that community transmission had been established as a scaling up of cases of COVID-19 had been observed in multiple sites in the country and on March 24, the State of Sao Paulo declared a statewide quarantine. Highly urbanized with a population of approximately 11.6 million people and a high level of socioeconomic inequality, São Paulo City has been the epicenter of the COVID-19 epidemics in Brazil since then, registering 560 cases per 100.000 inhabitants, compared to the national figure of 249 cases per 100.000 as of 31 May 2020 [2]. Due to an extremely low testing capacity, epidemic projections and policies addressing COVID-19 in Brazil have been designed without robust data to inform epidemic parameters. Seroprevalence surveys are important for measuring the proportion of the general population who have been infected and have produced SARS-CoV-2 antibodies [3], which in turn, may confer protection (at least in the short term) against the infection. We report results from a population-based household serosurvey planned to determine the prevalence of antibodies to SARS-CoV-2 in adults in six districts in São Paulo City, Brazil. We also investigated possible associations between

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

selected risk factors for SARS-CoV-2 infection and the presence of SARS-CoV-2 antibodies. **Methods** The design of this cross-sectional population-based study was designed informed by the World Health Organization (WHO) protocol for population-level COVID-19 antibody testing [4]. Study population and study ethics Six administrative districts of the São Paulo municipality were selected for the study because they were the most affected with COVID-19 according to official numbers of confirmed cases and suspected or confirmed deaths per 100.000 habitants as of April 23, 2020 [5]. Overall, 298.240 inhabitants aged 18 years old or more live in these districts [6]. All adults aged 18 years or older who were capable of understanding the information provided by the research teams were eligible to participate. A sample size of 500 households, one person per household, was planned to allow the estimation of the prevalence of seropositivity greater than 4% to be obtained under coefficients of variation of less than 30%. To allow for non-contact and refusals, 1049 households were randomly selected and surveyed. Between May 4 and May 12 2020, field teams approached all households and randomly selected one member from each household. After providing written and verbal information on the study, the team invited the selected resident to

participate. After obtaining informed consent from the participant, the team

applied a structured questionnaire to gather information on sociodemographic characteristics and occurrence of COVID-19-related symptoms in the previous two weeks. Blood was collected by venipuncture following the interview. Other household members (cohabitants) who were interested in participating in the study, followed the same procedures. The study was approved by the Fleury Institutional Ethical Committee (CAAE 31032620.0.0000.5474).

Specimen collection and laboratory tests

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

Samples were transported from the collection sites to the Serology Laboratory of Grupo Fleury where they were separated by centrifugation, aliquoted, and stored frozen until analysis, shortly after collection. All sera were tested for the presence of SARS-CoV-2 specific antibodies using the commercial kits "MAGLUMI IgM 2019-nCoV" "MAGLUMI IgG 2019-nCoV" (chemiluminescence and immunoassay-CLIA) supplied by Bioscience Co (China National Medical approval numbers Products Administration: 20203400183 (IgG) 20203400182 (IgM); and Brazilian ANVISA RE 860 and 861/2020). CLIA for IgG and IgM detection was developed based on a double-antibody sandwich immunoassay. The recombinant antigens containing the nucleoprotein and a peptide from the spike protein of SARS-CoV-2 were conjugated with FITC and immobilized on anti-FITC antibody-conjugated magnetic particles. Alkaline phosphatase-conjugated anti-human IgG and IgM was used as the detection antibody. The tests conducted automated were on an magnetic chemiluminescence analyzer (Axceed 260, Bioscience) according to the manufacturer's instructions. The antibody titer was tested once per serum sample.

Detecting IgM and IgG antibodies against SARS-CoV-2 depends on the number of days after the onset of symptoms. The diagnostic performance of CLIA has been evaluated in the literature [7-11]. Although the sensitivity and specificity improve during the progression of infection, sensitivity for IgM is 100% and specificity 94.1% twenty days after symptoms onset. The IgG sensitivity and specificity, twenty days after the onset of symptoms is 100% and 99.5% respectively [7]. To determine the reference values, samples from patients diagnosed with the COVID-19 RT-PCR test and samples from control groups such as blood donors, employees without flu symptoms vaccinated in 2020, a panel of samples that tested positive for other non-SARS-CoV-2 respiratory viruses, and samples from carriers of other infectious diseases were used. The results of analyzing of these samples led to the following reference values: IgG: reagent >1.1 UA/mL, indeterminate 0.9 to 1.1 UA/mL, non-reagent <0.9 UA/mL; and IgM: reagent >1.0 UA/mL, indeterminate 0.7 to 1.0 UA/mL, non-reagent <0.7 UA/mL. Individuals who were reactive to either IgM or IgG were considered positive.

## Data analysis

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

Prevalence estimates were obtained for two groups separately: randomly-selected residents and cohabitants. Data were analyzed for both groups and were weighted according to the sampling design, which in turn, were adjusted considering response rates and post-stratification by age and sex, according to the district population structure in 2020 [6]. Prevalence estimates with 95% confidence intervals (CI) were calculated for selected characteristics, and frequency distributions of self-reported symptoms were compared between

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

seropositive and seronegative individuals. Differences in proportions were assessed by the design-based F test. A p-value < 0.05 was considered to be statistically significant. Indeterminate results were included as negative in the analyses. STATA version 14 (StataCorp, College Station, TX, USA) was used for all statistical analyses. Results Out of 771 contacted households, 299 (38.5% participation rate) randomlyselected residents agreed to participate in the study, as did 218 cohabitants. The seroprevalence for SARS-CoV-2 was 4.8% (95%Cl 2.6-7.0%) for selected residents and overall seroprevalence, including test results for the 218 voluntary cohabitants, was 4.7% (95%CI 3.0-6.6%). Of the 27 SARS-CoV-2 seropositive individuals, 20 were IgG positive/IgM negative, six were IgG negative/IgM positive, and one was IgG positive/IgM positive. Socio-demographic characteristics of all 517 tested people stratified by SARS-CoV-2 seroprevalence estimates are shown in Table 1. Briefly, 54.9% were female, 52% aged between 18 and 44 years, 65% self-reported as being white and 46.4% had a university degree (16 years or more of schooling). Comparisons of seroprevalence show that people who reported brown and black skin color presented significantly higher SARS-CoV-2 seroprevalence compared to those with white skin. Nine or more years of schooling was associated with lower seroprevalence than low education level. Participants who reported one or more SARS-CoV-2-related symptoms in the past two weeks showed higher seropositivity than asymptomatic people, but this difference was not statistically significant (6.7% vs. 3.5%; P = .0801).

Frequencies of self-reported symptoms during the two-week-period before the survey stratified by SARS-CoV-2 seroreactivity are shown in Table 2. Twelve (45.3%) of the 27 seropositive individuals did not report symptoms. SARS-CoV-2-seropositive individuals were significantly more likely to experience symptoms such as fatigue, diarrhea, ageusia, and anosmia than seronegative residents. None of the seropositive individuals reported previous diagnoses of infection.

## **Discussion**

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

There are limited data available on the seroprevalence of SARS-CoV-2 infection in Brazil. In this study, an overall seroprevalence for anti-SARS-CoV-2 of 4.7% was observed. This estimate probably reflects the upper limit in the city of São Paulo since the selected districts were those with the highest number of cases and deaths in the city. One study, which used the Wondfo rapid antibody test, found a SARS-CoV-2 seroprevalence of 3.1% on May 17 [12]. Our findings were similar to this study, although seroprevalence estimates should be compared with caution, as the representativeness of the population covered, and laboratory testing methods differed between studies. Besides assessing the magnitude of the pandemic in chosen areas of São Paulo City, we looked at possible associations between selected risk factors for SARS-CoV-2 infection and the presence of SARS-CoV-2 antibodies. Previous reports have linked SARS-CoV-2 infections with no or minor symptoms [1,13,14]. We found results in the same direction, 45.3% of seropositive individuals reported no symptoms in the two weeks before the survey. Similar to studies on the frequency of SARS-CoV-2-related symptoms, anosmia, ageusia, fatigue and diarrhea were

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

symptoms associated with seropositivity [13,14]. It is noteworthy that SARS-CoV-2-related clinical symptoms and signs remain poorly documented in Brazil. The strengths of the current research are that it is the first household populationbased serosurvey in Brazil using a chemiluminescence assay, a very precise technique to detect immunoglobulins against SARS-CoV-2. This test together with the probabilistic sampling design provided a clear picture of the extent of human exposure to SARS-CoV-2 in the studied regions. There are some limitations to the study. First, since it was a cross-sectional study, temporal associations cannot be established and data are lacking on variables related to the epidemiology of SARS-CoV-2, such as the history of exposure and severity of symptoms. Second, refusal bias may have been introduced as a result of non-response, which occurred mainly due to non-cooperation by the managers of some residential blocks and to residents' unwillingness to donate blood. Third. we have not included children or young people under 18 years due to logistic restrictions. Last, the statistical power may have been insufficient to detect differences between subgroups. However, we believe that these issues have not affected our findings significantly, considering that our results are consistent with several worldwide reports that showed low prevalence of SARS-CoV-2 infection in the general population even in highly affected regions [12,13,15]. In conclusion, the overall exposure to SARS-CoV-2 in the general population in the research areas is low, indicating that a significant proportion of this population could still be infected. Following these initial results, a series of six monthly pointprevalence serosurveys, using similar methodology and the same testing method, has been initiated. By monitoring the SARS-CoV-2 seroprevalence in a population-representative sample, as well as the ongoing pandemic in São Paulo

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

City, high-risk groups and areas may be identified which will help guide public health actions. **Acknowledgments** We thank study participants whose cooperation made the study possible. We thank Pedro Passos, Guilherme Passos, Carlos Marinelli, A. Hernandez, A. Resende, D. Freitas, Fernando Pieroni, Jefferson Tolentino, Assis, L. S. Silva, V.A. Frascini, Willian Malfatti, Rosi Rosendo, Helio Neves, Sofia Reinach and Adriano Borges Costa for their help. We are grateful for the support of Dr Carolina dos Santos Lazari. References 1. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Med Infect Dis doi: 10.1016/j.tmaid.2020.101613. 2. Prefeitura do município de São Paulo, Secretaria da Saúde, Boletim Diário Covid-19. Number 66 on 31 May 2020 [Portuguese]. Available at: https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/202005 31 boletim covid19 diario.pdf. Accessed 10 June 2020. 3. Goudsmit J. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity [published online ahead of print, 21 April 2020]. Eur J Epidemiol doi:10.1007/s10654-020-00635-2.

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

4. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. https://www.who.int/publicationsdetail/population-based-age-stratifiedseroepidemiological-investigation-protocol-for-covid-19-virus infection. Accessed 8 April 2020. 5. Prefeitura do município de São Paulo, Secretaria da Saúde, Boletim Quinzenal Covid-19. Number 3 on 30 April 2020 [Portuguese]. https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/PMSP SMS COVID19 Boletim%20Quinzenal 20200430.pdf. Accessed 30 April 2020. 6. Fundação SEADE. Perfil dos municípios paulistas, 2020 [Portuguese]. https://perfil.seade.gov.br/?#. Accessed 30 April 2020. 7. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Med doi: 10.1038/s41591-020-0897-1. 8. Jin Y, Wang M, Zuo Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis doi: 10.1016/j.ijid.2020.03.065. 9. Lippi G, Salvagno GL, Pegoraro M, et al. Assessment of imune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med 2020; 58:1156-9. 10. Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Doiagnostic performance and thresholds: The key to harmonization in sorological SARS-CoV-2 assays? Clinica Chimica Acta 2020; 509:1-7.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

11. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performance of a chemiluminescence immunoassays for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med 2020; 58:1081-8. 12. Hallal PC, Hartwig FP, Horta BL, et al. Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states. medRxiv 2020.05.30.20117531. doi: 10.1101/2020.05.30.20117. 13. Tu H, Tu S, Gao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect 2020; 81:1-9. 14. Centers for Disease Control and Prevention (CDC) USA, 2020. Symptoms of novel coronavirus (2019-nCoV) on 2 June. https://www.cdc.gov/coronavirus/2019-ncov/symptomstesting/symptoms.html. Accessed 10 June 2020. 15. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG. [published online ahead of print, 11 June 2020]. Lancet doi: 10.1016/ S0140-6736(20)31304-0.

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

Footnote page Conflict of interests Statement: Authors associated with Grupo Fleury (C.F.H.G., M.C.P., E.R.) and Ibope Inteligência (M.C.N.) disclose the following potential conflict of interest: the two organizations are co-funding the project by providing their services at or below cost. These include data and blood sample collection and laboratory tests. The companies sell these services in the market and might profit from the publicity generated by the results of this research. B.H.T., M.C.G.P.A. and F.C.R. declare no conflict of interest. Funding Statement: The study received funding from Instituto Semeia, Grupo Fleury and Ibope Inteligência. # Corresponding author: Beatriz H. Tess, MD, PhD Departamento de Medicina Preventiva Faculdade de Medicina da USP Av. Dr. Arnaldo, 455, 2° andar 01246-903 São Paulo, SP, Brasil Tel.: (+ 55 11) 3061 7082 E-mail: <u>beatriz.tess@usp.br</u> Availability of data and materials: The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Table 1. SARS-CoV-2 seroprevalence, and 95% confidence interval, by selected population characteristics

Characteristic	N of	Seroprevalence*		p value**
	adults	%	95%CI	
Overall	517	4.7	3.0 - 6.6	-
Gender				
Female	284	4.2	2.2 – 7.8	0.5821
Male	233	5.4	3.1 – 9.2	
Age (years)				
18-44	269	4.3	2.5 - 7.3	0.5916
≥ 45	248	5.2	3.1 – 8.5	
Skin colour/race***				
White	335	3.3	1.9 – 5.6	0.0495****
Brown and black	147	8.6	4.7 – 15.0	
Asian and indigenous	30	3.5	0.5 - 22.5	
Education (years of schooling)				
≤8	59	11.6	5.4 - 23.0	0.0251****
9-15	218	4.1	2.2 – 7.2	
≥16	240	3.6	1.9 – 6.8	
SARS-CoV-2 related symptoms in the past				
2 weeks				
No symptom reported	312	3.5	2.1 – 5.8	0.0801
One or more symptoms reported	205	6.7	3.8 – 11.7	

<sup>304 \*</sup>corrected for sample design

303

<sup>305 \*\*</sup>design-based F test

<sup>306 \*\*\*</sup> missing data (n=5)

<sup>307 \*\*\*\*</sup> significant at 5%

Table 2: Frequency distribution, and 95% confidence interval, of self-reported symptoms in the last 14 days from date of survey by result of SARS-CoV-2 seroreactivity

Symptoms*	Seronegative		Seropositive			p value**	
	n	%	95%CI	n	%	95%CI	
Overall	190	37.5	32.8 – 42.4	15	54.7	35.5 – 72.6	0.0801
Fever	10	2.1	0.9 - 4.8	2	5.6	1.2 - 22.0	0.2525
Couch	79	15.4	12.1 - 19.4	6	20.6	9.4 - 39.4	0.4556
Shortness of breath	24	4.7	2.7 - 7.9	2	5.6	1.2 - 22.0	0.7492
Sore throat	46	9.3	7.3 – 11.7	3	8.1	2.5 - 23.5	0.8226
Rhinorrhea	107	21.0	17.1 – 25.5	7	25.5	12.5 – 45.2	0.5827
Fatigue	32	5.8	3.6 - 9.3	5	20.3	8.5 - 41.2	0.0040***
Myalgia	46	8.9	6.2 - 12.7	6	18.8	8.3 - 37.1	0.0528
Diarrhea	28	5.5	3.7 - 8.0	4	13.2	5.3 - 29.0	0.0408***
Ageusia	14	2.9	1.6 - 5.3	6	18.4	7.1 - 39.7	0.0003***
Anosmia	15	3.0	1.7 – 5.4	6	18.4	7.1 - 39.7	0.0002***

313 \* single or multiple symptoms

314 \*\*design-based F test

315 \*\*\* significant at 5%

311

312